US20040135571A1 - Artifact removal from an electric signal - Google Patents

Artifact removal from an electric signal Download PDF

Info

Publication number
US20040135571A1
US20040135571A1 US10/724,347 US72434703A US2004135571A1 US 20040135571 A1 US20040135571 A1 US 20040135571A1 US 72434703 A US72434703 A US 72434703A US 2004135571 A1 US2004135571 A1 US 2004135571A1
Authority
US
United States
Prior art keywords
samples
sequence
signal
interference
downsampling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10/724,347
Other versions
US7038601B2 (en
Inventor
Kimmo Uutela
Tor Rantala
Juha Virtanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instrumentarium Oyj
Original Assignee
Instrumentarium Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instrumentarium Oyj filed Critical Instrumentarium Oyj
Assigned to INSTRUMENTARIUM CORP. reassignment INSTRUMENTARIUM CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RANTALA, TOR BORJE, UUTELA, KIMMO HENRIK, VIRTANEN, JUHA PETRI
Publication of US20040135571A1 publication Critical patent/US20040135571A1/en
Application granted granted Critical
Publication of US7038601B2 publication Critical patent/US7038601B2/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316Modalities, i.e. specific diagnostic methods
    • A61B5/318Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316Modalities, i.e. specific diagnostic methods

Definitions

  • the present invention relates generally to a method and apparatus for suppressing or removing artifacts from an electric signal.
  • the term “artifact” here refers to interference which has a certain structure and is therefore not noise-like random interference.
  • the invention is intended especially for medical technology to eliminate artifact components from an electrocardiogram (ECG) signal in connection with magnetic resonance imaging (MRI), but the method can be applied to any systems in which an artifact component similar to the one caused by an MRI device to an ECG signal is superimposed on a useful signal.
  • Artifact components are typically caused by sources which are external to the apparatus receiving the useful signal.
  • MRI Magnetic Resonance Imaging
  • MRI Magnetic Resonance Imaging
  • Radio waves are simultaneously transmitted to the patient, and images of the interior of the body are obtained by means of a computer analysis of the radio waves received from the patient.
  • the condition of the patient is constantly monitored. This includes the monitoring of the ECG signal of the patient, for example.
  • One drawback related to the monitoring is that the intense magnetic fields of the imaging device induce interference with the ECG signal of the patient. This interference, which is termed here an artifact, is short-termed and strong, and appears very frequently.
  • FIG. 1 a and 1 b show a typical example of the narrow and strong interference peaks caused to the ECG signal by MRI measurement.
  • FIG. 1 a illustrates a sequence of the narrow interference pulses superimposed on the ECG signal
  • FIG. 1 b illustrates the shape and length of one interference pulse.
  • the artifact is usually rather similar for each MR image acquired and consists of a few short peaks.
  • the shape of an interference peak is roughly box-like, with a relatively constant period between the steepest rise and fall edges.
  • a natural way of detecting the MRI gradient peaks is to monitor the rise and/or fall speed, i.e. the slew rate, of the ECG signal.
  • a solution based on a slew rate limiter is disclosed in U.S. Pat. No. 4,991,580. This patent presents a method whereby the ECG signal is supplied to the input of a slew rate limiter (SRL) circuit, which limits the slew rate of the ECG to a pre-selected maximum value slightly greater than a typical maximum slew rate in an ECG signal.
  • SRL slew rate limiter
  • This patent describes a cardiac monitor in connection with an MRI device, the monitor to include a comparator which compares each wave form received from the ECG electrodes with the properties of a cardiac signal, such as the slope.
  • the comparator detects interference in the ECG signal, it gates a track and hold circuit.
  • the track and hold circuit passes the ECG signal, except when gated by the comparator.
  • the track and hold circuit continues to supply the same output voltage it had at the beginning of the gating period, i.e. it freezes the ECG signal for the period of interference.
  • U.S. Pat. No. 4,243,045 presents a method for the suppression of narrow interference pulse peaks and of interference hum in a useful signal.
  • the method is intended particularly for suppressing the pacemaker pulses and the power supply hum superimposed on an ECG signal.
  • the narrow pulses caused by the pacemaker are blanked out by keeping the signal constant for the blanking-out period, and the power supply hum is eliminated by an interference hum filter.
  • the filtered-out interference hum component is opposingly superimposed on the original signal to compensate for the interference hum.
  • the prior art methods based on freezing the signal entail the fundamental drawback of not being able to take into account signal changes occurring during the freezing period.
  • the methods based on limitation of the slew rate in turn, involve the fundamental drawback that some of the interference remains in the useful signal, as the methods limit only the size of the interference. For these reasons, the prior art methods may leave errors of substantial magnitudes affecting the useful signal.
  • the objective of the present invention is to bring about a solution for eliminating as accurately as possible narrow interference peaks from a useful signal, such as MRI-induced artifacts from an ECG signal.
  • the useful signal is first sampled at a high sampling frequency.
  • the samples are then supplied to an artifact detection process during which the degraded samples are identified, i.e. it is detected which of the samples are degraded by the artifact and which are essentially free of artifact and thus good samples.
  • the selected high quality samples of the useful signal are then utilized in a subsequent downsampling process, which is in this context termed an artifact-aware downsampling, since the preceding detection process indicates the samples containing an artifact component. More particularly, in the downsampling process, samples considered as free of artifact are used to generate a new sequence of samples having a sampling frequency substantially lower than the original sampling frequency.
  • the downsampling process thus constructs a new sample sequence with a reduced sampling rate. Consequently, the method of the invention includes a controlled downsampling of the original signal, the downsampling being controlled by the artifact-content of the high rate sample sequence.
  • one aspect of the invention is providing a method for suppressing interference in an electric signal, the method comprising the steps of
  • the method of the invention improves the accuracy of artifact elimination, since it does not limit or freeze the signal values. Instead, the signal is sampled at a high rate, the artifact-content of the samples is detected, and the detected artifact content controls the downsampling of the signal so that only high quality samples are utilized.
  • Another aspect of the invention is that of providing an apparatus for suppressing interference in an electric signal, the apparatus comprising
  • sampling means for sampling the electric signal at a first sampling frequency, whereby a first sequence of samples is obtained
  • selection means for selecting some of the samples in the first sequence on the basis of predetermined criteria
  • downsampling means operatively connected to the selection means, for downsampling the first sequence by using the selected samples, whereby a second sequence of samples is obtained, the second sequence forming a digital presentation of the electric signal in which the interference is suppressed.
  • the samples of the first sequence are compared with a reference signal generated from the original useful signal, whereby the selecting step is performed based on the comparing step.
  • information about the artifact content of the samples is generated as a result of the comparison of the signal with the reference.
  • the information generated is supplied, together with the samples, to the downsampling process, where the signal is downsampled using this information.
  • the information consists preferably of a sequence of flags, each flag being attached to the relevant sample and indicating where the sample is artifact-free or not.
  • the power supply hum is eliminated from the ECG signal before the downsampling process.
  • This is implemented by first calculating the amount of power supply hum in the ECG signal by using the artifact-free samples only. The calculated value of the hum at each sample is then deducted from the corresponding sample, whereby updated sample values are obtained for the high rate sample sequence. In this way the power supply hum appearing in the signal can be efficiently removed.
  • one advantage of the method of the invention is that it allows simultaneous and efficient suppression of both MRI induced artifacts and power supply hum.
  • FIG. 1 a illustrates the artifact superimposed on an ECG signal in connection with magnetic resonance imaging (MRI)
  • FIG. 1 b illustrates one artifact pulse in FIG. 1 a
  • FIG. 2 illustrates the apparatus according to the invention
  • FIG. 3 a illustrates one embodiment of the method of the invention
  • FIG. 3 b illustrates a second embodiment of the method of the invention
  • FIG. 3 c illustrates a third embodiment of the method of the invention.
  • FIG. 2 is a schematic presentation of the apparatus according to the present invention.
  • the signal received from the ECG sensor(s) is supplied to an amplifier stage 210 , which amplifies the signal before it is sampled and converted into digitized format in an A/D converter 220 .
  • a high sampling rate is used in the A/D converter to sample the ECG signal.
  • a typical sampling rate could be of the order of 10 kHz, for example, which yields about 10 samples during one interference peak (cf. FIG. 1 b ).
  • the initial sampling rate used in the present invention is higher than the sampling rate needed for the original signal, the latter being typically 100 to 1000 Hz in the case of an ECG signal.
  • a high rate sample sequence HRS is obtained, which is buffered and processed in a digital signal processing unit 230 .
  • the processing unit performs the removal of the artifacts and outputs the corrected ECG signal, i.e. the original ECG signal from which the artifacts have been removed.
  • FIG. 3 a illustrates one embodiment of the method performed in the digital signal processing unit 230 .
  • a separate reference signal is first formed from the high rate sample sequence HRS (step 310 ).
  • This reference signal is preferably generated from the sample sequence itself, through the use of a slew rate limiter, for example.
  • the reference signal is preferably generated by copying the input signal and limiting the slew rate in the copy.
  • the reference signal serves as a reference for identifying the artifact in the original input signal.
  • the reference signal may also be an external signal, i.e. a signal which is not derived from the ECG signal input to the signal processing unit.
  • the MRI device for example, can provide an external reference signal whose high amplitude levels identify the samples containing an artifact component.
  • the actual method of generating the reference signal is not essential.
  • the samples of the input signal containing an artifact component are then identified (step 320 ). Although these samples can be identified by comparing an external reference signal, such as the above-mentioned signal provided by the MRI device, to a predetermined threshold, it is assumed here that the said samples are identified by comparing the input signal, i.e. the original ECG signal, with the reference signal generated from the original ECG signal by limiting the slew rate. The comparison is performed by comparing each sample of the input signal to the corresponding sample of the reference signal. When a sample of the input signal meets predefined criteria, it is considered as an artifact-free sample. Different criteria may be used in determining when a sample is artifact-free. In this example, when the input signal and the reference signal are within the noise level of each other, the sample is considered artifact-free and thus valid.
  • an external reference signal such as the above-mentioned signal provided by the MRI device
  • the selection is implemented as follows. First, on the basis of the results of the comparison process, information is generated about the validity of each sample of the input signal. This information preferably consists of a sequence of flags, one flag being attached to each sample of the input signal, to indicate whether the corresponding sample is valid (i.e. free from an artifact). Second, the samples and the associated flags are forwarded for the downsampling process, during which the digital input signal is downsampled utilizing the information about the validity of the samples, i.e. the flag sequence (step 340 ).
  • the process is here called artifact-aware downsampling. Based on the information, only artifact-free samples are selected, and the downsampling is performed based on these samples only.
  • the actual downsampling can be performed in many ways, which are known in the art.
  • integer downsampling ratios the most common approach is to use an anti-aliasing low-pass filter and then to select every n th sample.
  • non-integer downsampling ratios the signal is usually first upsampled by padding the signal with zeros, the signal is then low-pass filtered, and then the desired samples are selected (every n th sample). To keep the individual sample rate changes small, the whole process is often divided up into several stages with smaller sampling rate ratios.
  • Another approach used for downsampling is interpolation: the signal at the correct point in time is calculated by modeling the neighboring values. Methods typically used are to select the value of the nearest neighbor or to model the signal using a polynomial function or spline.
  • the sample rate of this sequence can be 300 Hz, for example.
  • the new sequence forms the digital presentation of the ECG signal from which the artifact has been removed.
  • FIG. 3 b illustrates a preferred embodiment of the method performed in the digital signal processing unit.
  • this embodiment includes the elimination of power supply hum, i.e. elimination of the interference at 50 or 60 Hz caused by a power supply.
  • power supply hum i.e. elimination of the interference at 50 or 60 Hz caused by a power supply.
  • each output sample is based on input samples having very small artifact levels. However, since the good samples are taken from varying parts of the time window, the output may have a disturbance resembling temporal jitter in the sampling. This will deform the signal slightly, whereby the signal can interfere with a notch filter intended to remove the 50/60 Hz power supply hum.
  • the power supply hum is removed before downsampling (step 330 ).
  • the elimination can be implemented by estimating the amplitude and phase of the power supply hum and removing the estimated hum from the input signal, i.e. subtracting the estimated hum from the original signal.
  • the estimation is implemented by using only the samples considered as good ones when calculating the amplitude and phase of the power supply hum.
  • the power hum estimate can be calculated by means of a band-pass filter, which is thus an artifact-aware filter as it uses the good samples only.
  • the artifact-aware downsampling can be obtained by calculating the weighted averages of only the good samples with their normal weights and by correcting the gain based on the weights of the bad samples. For example, if the FIR filter is a boxcar filter, the artifact-aware downsampling process, i.e. the filter, calculates the average of the corresponding good samples, said average to form the value of one low rate sample.
  • the standard interpolation means can be applied by taking into account the good samples and the corresponding moments in the time domain.
  • the above-mentioned artifact-aware downsampling is combined with artifact-aware low-pass filtering.
  • the filter can be replaced by an artifact-aware FIR filter using the number of good samples as the flag. This kind of implementation further improves the accuracy of the apparatus, and it may also be more tolerant to long periods of noise.
  • Low-pass filtering may be a separate step subsequent to downsampling, or it may be divided into two stages, of which the first one is formed by the above-mentioned low-pass filtering in the downsampling process.
  • the second stage may then occur after the downsampling, whereby the filtering in the second stage is applied to the lower rate sample sequence.
  • the division of low-pass filtering into two stages is advantageous in terms of calculating power; the processing time is shorter if the filtering is divided into two stages of which the first one provides rough filtering and the second one is a more accurate stage.
  • the use of low-pass filtering is illustrated in FIG. 3c.
  • the low-pass filtering stage 350 of receiving the low rate sample sequence and the corresponding low rate flag sequence can thus form the only low-pass filtering stage of the apparatus or it can complement the low-pass filtering performed at stage 340 .
  • an indication may be given of the magnitude of the artifact contained in the sample.
  • the artifact components can be classified into several categories depending on their magnitude.
  • the flag sequence supplied for stage 350 can be numeric, and the FIR filter can be implemented by using all the samples but having different weights for each sample.
  • x is the input signal
  • b is the filter coefficient vector
  • f is the flag sequence vector.
  • a binary flag sequence is represented with zeros for bad samples and with ones for good samples.
  • the artifact-aware band-pass filter producing the estimated power supply hum sequence at step 330 may be implemented according to equation (2), for example:

Abstract

The invention relates to a method and apparatus for suppressing interference in an electric signal, particularly for suppressing interference in an electrocardiogram (ECG) signal in connection with magnetic resonance imaging (MRI). In order to improve the accuracy of the suppression, the electric signal is first sampled at a high sampling frequency, whereby a first sequence of samples is obtained. Some of the samples in the first sequence of samples are then selected on the basis of predetermined criteria. The first sequence is then downsampled using the selected samples, whereby a second sequence of samples is obtained. The second sequence forms a digital presentation of the electric signal in which the interference is suppressed.

Description

    FIELD OF THE INVENTION
  • The present invention relates generally to a method and apparatus for suppressing or removing artifacts from an electric signal. The term “artifact” here refers to interference which has a certain structure and is therefore not noise-like random interference. The invention is intended especially for medical technology to eliminate artifact components from an electrocardiogram (ECG) signal in connection with magnetic resonance imaging (MRI), but the method can be applied to any systems in which an artifact component similar to the one caused by an MRI device to an ECG signal is superimposed on a useful signal. Artifact components are typically caused by sources which are external to the apparatus receiving the useful signal. [0001]
  • BACKGROUND OF THE INVENTION
  • As is known, MRI (Magnetic Resonance Imaging) is a technique used for getting images of a body without the use of X-rays. In MRI, the patient is placed within a rapidly changing magnetic field created by the MRI device. Radio waves are simultaneously transmitted to the patient, and images of the interior of the body are obtained by means of a computer analysis of the radio waves received from the patient. [0002]
  • During the imaging, the condition of the patient is constantly monitored. This includes the monitoring of the ECG signal of the patient, for example. One drawback related to the monitoring is that the intense magnetic fields of the imaging device induce interference with the ECG signal of the patient. This interference, which is termed here an artifact, is short-termed and strong, and appears very frequently. [0003]
  • FIG. 1[0004] a and 1 b show a typical example of the narrow and strong interference peaks caused to the ECG signal by MRI measurement. FIG. 1a illustrates a sequence of the narrow interference pulses superimposed on the ECG signal, while FIG. 1b illustrates the shape and length of one interference pulse. The artifact is usually rather similar for each MR image acquired and consists of a few short peaks. The shape of an interference peak is roughly box-like, with a relatively constant period between the steepest rise and fall edges.
  • The prior art methods intended for suppressing the above-described artifacts are based on either limiting the rise and fall speed of the ECG signal or freezing the signal during the interference periods. In the following these prior art methods are discussed briefly. [0005]
  • A natural way of detecting the MRI gradient peaks is to monitor the rise and/or fall speed, i.e. the slew rate, of the ECG signal. A solution based on a slew rate limiter is disclosed in U.S. Pat. No. 4,991,580. This patent presents a method whereby the ECG signal is supplied to the input of a slew rate limiter (SRL) circuit, which limits the slew rate of the ECG to a pre-selected maximum value slightly greater than a typical maximum slew rate in an ECG signal. [0006]
  • Another approach for eliminating MRI induced artifacts superimposed on an ECG signal is presented in U.S. Pat. No. 5,038,785. This patent describes a cardiac monitor in connection with an MRI device, the monitor to include a comparator which compares each wave form received from the ECG electrodes with the properties of a cardiac signal, such as the slope. When the comparator detects interference in the ECG signal, it gates a track and hold circuit. The track and hold circuit passes the ECG signal, except when gated by the comparator. When gated by the comparator, the track and hold circuit continues to supply the same output voltage it had at the beginning of the gating period, i.e. it freezes the ECG signal for the period of interference. [0007]
  • U.S. Pat. No. 4,243,045 presents a method for the suppression of narrow interference pulse peaks and of interference hum in a useful signal. The method is intended particularly for suppressing the pacemaker pulses and the power supply hum superimposed on an ECG signal. The narrow pulses caused by the pacemaker are blanked out by keeping the signal constant for the blanking-out period, and the power supply hum is eliminated by an interference hum filter. The filtered-out interference hum component is opposingly superimposed on the original signal to compensate for the interference hum. [0008]
  • The prior art methods based on freezing the signal entail the fundamental drawback of not being able to take into account signal changes occurring during the freezing period. The methods based on limitation of the slew rate, in turn, involve the fundamental drawback that some of the interference remains in the useful signal, as the methods limit only the size of the interference. For these reasons, the prior art methods may leave errors of substantial magnitudes affecting the useful signal. [0009]
  • It is the objective of the invention to improve the accuracy of the methods described above and to bring about a new and efficient solution for suppressing or eliminating artifacts from a useful signal, particularly MRI-induced artifacts from an ECG signal. [0010]
  • SUMMARY OF THE INVENTION
  • The objective of the present invention is to bring about a solution for eliminating as accurately as possible narrow interference peaks from a useful signal, such as MRI-induced artifacts from an ECG signal. [0011]
  • According to the invention, the useful signal is first sampled at a high sampling frequency. The samples are then supplied to an artifact detection process during which the degraded samples are identified, i.e. it is detected which of the samples are degraded by the artifact and which are essentially free of artifact and thus good samples. The selected high quality samples of the useful signal are then utilized in a subsequent downsampling process, which is in this context termed an artifact-aware downsampling, since the preceding detection process indicates the samples containing an artifact component. More particularly, in the downsampling process, samples considered as free of artifact are used to generate a new sequence of samples having a sampling frequency substantially lower than the original sampling frequency. By utilizing the artifact-free samples only, the downsampling process thus constructs a new sample sequence with a reduced sampling rate. Consequently, the method of the invention includes a controlled downsampling of the original signal, the downsampling being controlled by the artifact-content of the high rate sample sequence. [0012]
  • Thus one aspect of the invention is providing a method for suppressing interference in an electric signal, the method comprising the steps of [0013]
  • sampling the electric signal at a first sampling frequency, whereby a first sequence of samples is obtained, [0014]
  • selecting some of the samples in the first sequence of samples on the basis of predetermined criteria, and [0015]
  • downsampling said first sequence using the selected samples, whereby a second sequence of samples is obtained, the second sequence forming a digital presentation of the electric signal in which the interference is suppressed. [0016]
  • The method of the invention improves the accuracy of artifact elimination, since it does not limit or freeze the signal values. Instead, the signal is sampled at a high rate, the artifact-content of the samples is detected, and the detected artifact content controls the downsampling of the signal so that only high quality samples are utilized. [0017]
  • Another aspect of the invention is that of providing an apparatus for suppressing interference in an electric signal, the apparatus comprising [0018]
  • sampling means for sampling the electric signal at a first sampling frequency, whereby a first sequence of samples is obtained, [0019]
  • selection means for selecting some of the samples in the first sequence on the basis of predetermined criteria, and [0020]
  • downsampling means, operatively connected to the selection means, for downsampling the first sequence by using the selected samples, whereby a second sequence of samples is obtained, the second sequence forming a digital presentation of the electric signal in which the interference is suppressed. [0021]
  • In a preferred embodiment of the invention, the samples of the first sequence are compared with a reference signal generated from the original useful signal, whereby the selecting step is performed based on the comparing step. [0022]
  • In a further preferred embodiment of the invention, information about the artifact content of the samples is generated as a result of the comparison of the signal with the reference. The information generated is supplied, together with the samples, to the downsampling process, where the signal is downsampled using this information. The information consists preferably of a sequence of flags, each flag being attached to the relevant sample and indicating where the sample is artifact-free or not. [0023]
  • In another preferred embodiment of the invention, the power supply hum, possibly appearing at 50 or 60 Hz and superimposed on the ECG signal, is eliminated from the ECG signal before the downsampling process. This is implemented by first calculating the amount of power supply hum in the ECG signal by using the artifact-free samples only. The calculated value of the hum at each sample is then deducted from the corresponding sample, whereby updated sample values are obtained for the high rate sample sequence. In this way the power supply hum appearing in the signal can be efficiently removed. Thus one advantage of the method of the invention is that it allows simultaneous and efficient suppression of both MRI induced artifacts and power supply hum. [0024]
  • Other features and advantages of the invention will become apparent by reference to the following detailed description and accompanying drawings. [0025]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • In the following, the invention and its preferred embodiments are described more closely with reference to the examples shown in FIGS. [0026] 2 to 3 c in the appended drawings, wherein:
  • FIG. 1[0027] a illustrates the artifact superimposed on an ECG signal in connection with magnetic resonance imaging (MRI),
  • FIG. 1[0028] b illustrates one artifact pulse in FIG. 1a,
  • FIG. 2 illustrates the apparatus according to the invention, [0029]
  • FIG. 3[0030] a illustrates one embodiment of the method of the invention,
  • FIG. 3[0031] b illustrates a second embodiment of the method of the invention, and
  • FIG. 3[0032] c illustrates a third embodiment of the method of the invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • FIG. 2 is a schematic presentation of the apparatus according to the present invention. The signal received from the ECG sensor(s) is supplied to an [0033] amplifier stage 210, which amplifies the signal before it is sampled and converted into digitized format in an A/D converter 220. A high sampling rate is used in the A/D converter to sample the ECG signal. A typical sampling rate could be of the order of 10 kHz, for example, which yields about 10 samples during one interference peak (cf. FIG. 1b). In any case, the initial sampling rate used in the present invention is higher than the sampling rate needed for the original signal, the latter being typically 100 to 1000 Hz in the case of an ECG signal.
  • As a result of the sampling, a high rate sample sequence HRS is obtained, which is buffered and processed in a digital [0034] signal processing unit 230. The processing unit performs the removal of the artifacts and outputs the corrected ECG signal, i.e. the original ECG signal from which the artifacts have been removed.
  • FIG. 3[0035] a illustrates one embodiment of the method performed in the digital signal processing unit 230. A separate reference signal is first formed from the high rate sample sequence HRS (step 310). This reference signal is preferably generated from the sample sequence itself, through the use of a slew rate limiter, for example. In other words, the reference signal is preferably generated by copying the input signal and limiting the slew rate in the copy. The reference signal serves as a reference for identifying the artifact in the original input signal.
  • Instead of being generated from the input signal, the reference signal may also be an external signal, i.e. a signal which is not derived from the ECG signal input to the signal processing unit. The MRI device, for example, can provide an external reference signal whose high amplitude levels identify the samples containing an artifact component. In view of the invention, the actual method of generating the reference signal is not essential. [0036]
  • The samples of the input signal containing an artifact component are then identified (step [0037] 320). Although these samples can be identified by comparing an external reference signal, such as the above-mentioned signal provided by the MRI device, to a predetermined threshold, it is assumed here that the said samples are identified by comparing the input signal, i.e. the original ECG signal, with the reference signal generated from the original ECG signal by limiting the slew rate. The comparison is performed by comparing each sample of the input signal to the corresponding sample of the reference signal. When a sample of the input signal meets predefined criteria, it is considered as an artifact-free sample. Different criteria may be used in determining when a sample is artifact-free. In this example, when the input signal and the reference signal are within the noise level of each other, the sample is considered artifact-free and thus valid.
  • Based on the comparison process at [0038] step 320, some of the high rate samples are selected and the selected samples are forwarded for a downsampling process. In the embodiment of FIG. 3a, the selection is implemented as follows. First, on the basis of the results of the comparison process, information is generated about the validity of each sample of the input signal. This information preferably consists of a sequence of flags, one flag being attached to each sample of the input signal, to indicate whether the corresponding sample is valid (i.e. free from an artifact). Second, the samples and the associated flags are forwarded for the downsampling process, during which the digital input signal is downsampled utilizing the information about the validity of the samples, i.e. the flag sequence (step 340). As the information about the artifact content of the samples, i.e. the flag sequence, is forwarded for the downsampling process, the process is here called artifact-aware downsampling. Based on the information, only artifact-free samples are selected, and the downsampling is performed based on these samples only.
  • It is to be noted here that it is preferred not to discard the samples affected by artifacts before entering the downsampling process, but instead all the samples are supplied for said process, together with the flag sequence, so that the downsampling process receives the information about the locations in the time domain of the good and bad samples. Another alternative is to discard the samples which are identified as having been affected by artifacts and to supply only the good samples for the downsampling process. However, this alternative requires that the significant moments corresponding to the good samples are forwarded for the downsampling process. [0039]
  • The actual downsampling can be performed in many ways, which are known in the art. For integer downsampling ratios, the most common approach is to use an anti-aliasing low-pass filter and then to select every n[0040] th sample. For non-integer downsampling ratios, the signal is usually first upsampled by padding the signal with zeros, the signal is then low-pass filtered, and then the desired samples are selected (every nth sample). To keep the individual sample rate changes small, the whole process is often divided up into several stages with smaller sampling rate ratios.
  • Another approach used for downsampling is interpolation: the signal at the correct point in time is calculated by modeling the neighboring values. Methods typically used are to select the value of the nearest neighbor or to model the signal using a polynomial function or spline. [0041]
  • As a result of the downsampling, a new sample sequence with a lower sample rate is obtained. The sample rate of this sequence can be 300 Hz, for example. The new sequence forms the digital presentation of the ECG signal from which the artifact has been removed. [0042]
  • FIG. 3[0043] b illustrates a preferred embodiment of the method performed in the digital signal processing unit. In addition to the functions described in connection with FIG. 3a, this embodiment includes the elimination of power supply hum, i.e. elimination of the interference at 50 or 60 Hz caused by a power supply. In the artifact-aware downsampling described above, each output sample is based on input samples having very small artifact levels. However, since the good samples are taken from varying parts of the time window, the output may have a disturbance resembling temporal jitter in the sampling. This will deform the signal slightly, whereby the signal can interfere with a notch filter intended to remove the 50/60 Hz power supply hum. Therefore, better results can be achieved by using the solution of FIG. 3b, where the power supply hum is removed before downsampling (step 330). The elimination can be implemented by estimating the amplitude and phase of the power supply hum and removing the estimated hum from the input signal, i.e. subtracting the estimated hum from the original signal. The estimation is implemented by using only the samples considered as good ones when calculating the amplitude and phase of the power supply hum. Thus in the process of removing power supply hum, the information about the artifact content of the samples is utilized, similarly as in the downsampling process. The power hum estimate can be calculated by means of a band-pass filter, which is thus an artifact-aware filter as it uses the good samples only.
  • When the downsampling process comprises a FIR filter, the artifact-aware downsampling can be obtained by calculating the weighted averages of only the good samples with their normal weights and by correcting the gain based on the weights of the bad samples. For example, if the FIR filter is a boxcar filter, the artifact-aware downsampling process, i.e. the filter, calculates the average of the corresponding good samples, said average to form the value of one low rate sample. [0044]
  • When the downsampling process includes interpolation, the standard interpolation means can be applied by taking into account the good samples and the corresponding moments in the time domain. [0045]
  • In a further preferred embodiment of the invention, the above-mentioned artifact-aware downsampling is combined with artifact-aware low-pass filtering. The filter can be replaced by an artifact-aware FIR filter using the number of good samples as the flag. This kind of implementation further improves the accuracy of the apparatus, and it may also be more tolerant to long periods of noise. [0046]
  • Low-pass filtering may be a separate step subsequent to downsampling, or it may be divided into two stages, of which the first one is formed by the above-mentioned low-pass filtering in the downsampling process. The second stage may then occur after the downsampling, whereby the filtering in the second stage is applied to the lower rate sample sequence. The division of low-pass filtering into two stages is advantageous in terms of calculating power; the processing time is shorter if the filtering is divided into two stages of which the first one provides rough filtering and the second one is a more accurate stage. The use of low-pass filtering is illustrated in FIG. 3c. The low-[0047] pass filtering stage 350 of receiving the low rate sample sequence and the corresponding low rate flag sequence can thus form the only low-pass filtering stage of the apparatus or it can complement the low-pass filtering performed at stage 340.
  • By using more than one bit in the flag, an indication may be given of the magnitude of the artifact contained in the sample. In this way the artifact components can be classified into several categories depending on their magnitude. As the quality of a low rate sample calculated depends on the number of high rate samples used to produce it, the flag sequence supplied for [0048] stage 350 can be numeric, and the FIR filter can be implemented by using all the samples but having different weights for each sample.
  • The artifact-aware FIR filter may be implemented according to equation (1), for example: [0049] y = i f i b i x i × i b i i f i b i ( 1 )
    Figure US20040135571A1-20040715-M00001
  • where x is the input signal, b is the filter coefficient vector, and f is the flag sequence vector. A binary flag sequence is represented with zeros for bad samples and with ones for good samples. [0050]
  • The artifact-aware band-pass filter producing the estimated power supply hum sequence at [0051] step 330 may be implemented according to equation (2), for example:
  • y p =A(FA)+ Fx   (2)
  • where the elements of the n×2 matrix A are A[0052] i,1=sin(2πi/n) and Ai,2=cos(2πi/n), F is a diagonal matrix having the flag sequence as the diagonal elements, (.)+ is the Moore-Penrose pseudoinverse, and x is the input signal.
  • Although the invention was described above with reference to the examples shown in the appended drawings, it is obvious that the invention is not limited to these, but may be modified by those skilled in the art without departing from the scope and spirit of the invention. Even if the method was described with reference to the MRI-induced artifact superimposed on the ECG signal, the method can be applied to any system in which an artifact component with like properties is superimposed on a useful signal. [0053]

Claims (14)

1. A method for suppressing interference in an electric signal, the method comprising the steps of
sampling the electric signal at a first sampling frequency, whereby a first sequence of samples is obtained,
selecting some of the samples in the first sequence of samples on the basis of predetermined criteria, and
downsampling said first sequence using the selected samples, whereby a second sequence of samples is obtained, the second sequence forming a digital presentation of the electric signal in which the interference is suppressed.
2. A method according to claim 1, further comprising the step of comparing the samples of the first sequence with a reference signal, whereby the selecting step is performed based on the comparing step.
3. A method according to claim 1, further comprising the step of generating information about the interference content in the samples, whereby the selecting step is performed on the basis of said information.
4. A method according to claim 2, wherein the reference signal is formed from said first sequence of samples by limiting the slew rate in said sequence.
5. A method according to claim 3, wherein the generating step includes attaching a flag to each of the samples, the flag to indicate whether the sample is free of interference or not.
6. A method according to claim 5, wherein the selecting step includes selecting the samples with the flag indicating that the corresponding sample is free of interference.
7. A method according to claim 1, further comprising the step of suppressing power supply hum in the first sequence of samples, whereby values of said samples are updated according to the amount of the power supply hum.
8. A method according to claim 7, wherein the suppressing step includes
estimating the power supply hum based on the first sequence of samples, and
deducting the estimated power supply hum from the first sequence, whereby the values of said samples are updated accordingly.
9. A method according to claim 1, wherein the downsampling step includes low-pass filtering the first sequence.
10. A method according to claim 1, further comprising the step of low-pass filtering the second sequence of samples.
11. An apparatus for suppressing interference in an electric signal, the apparatus comprising
sampling means for sampling the electric signal at a first sampling frequency, whereby a first sequence of samples is obtained,
selection means for selecting some of the samples in the first sequence on the basis of predetermined criteria, and
downsampling means, operatively connected to the selection means, for downsampling the first sequence by using the selected samples, whereby a second sequence of samples is obtained, the second sequence forming a digital presentation of the electric signal in which the interference is suppressed.
12. An apparatus according to claim 11, further comprising comparison means for comparing the first sequence of samples with a reference signal, the selection means being operatively connected to the comparison means.
13. An apparatus according to claim 11, further comprising means for generating information about the interference content in the samples of the first sequence, whereby said selection means are adapted to select the samples based on the information.
14. An apparatus according to claim 11, further comprising
means for estimating the amount of power supply hum in the first sequence, and
means for updating the samples in the first sequence based on the estimated amount of the power supply hum.
US10/724,347 2002-11-29 2003-11-26 Artifact removal from an electric signal Expired - Fee Related US7038601B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02396178A EP1424637A1 (en) 2002-11-29 2002-11-29 Artifact removal from an electric signal
EP02396178.2 2002-11-29

Publications (2)

Publication Number Publication Date
US20040135571A1 true US20040135571A1 (en) 2004-07-15
US7038601B2 US7038601B2 (en) 2006-05-02

Family

ID=32241365

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/724,347 Expired - Fee Related US7038601B2 (en) 2002-11-29 2003-11-26 Artifact removal from an electric signal

Country Status (2)

Country Link
US (1) US7038601B2 (en)
EP (1) EP1424637A1 (en)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025382A1 (en) * 2005-09-01 2007-03-08 Les Systèmes Nuax Computer mouse pressure acquisition module
US20080004537A1 (en) * 2006-06-30 2008-01-03 Kimmo Uutela Method and system for multi-channel biosignal processing
US20080146892A1 (en) * 2006-12-19 2008-06-19 Valencell, Inc. Physiological and environmental monitoring systems and methods
US20080208276A1 (en) * 2007-02-28 2008-08-28 Cardiac Pacemakers, Inc. Induced Current Measurement Systems And Methods
US20080221638A1 (en) * 2007-03-09 2008-09-11 Cardiac Pacemakers, Inc. MRI Compatible Implantable Medical Devices and Methods
US20080228092A1 (en) * 2007-03-14 2008-09-18 Wedan Steven R Cardiac Sensing by Implantable Medical Devices During Magnetic Resonance Imaging
US20100161779A1 (en) * 2008-12-24 2010-06-24 Verizon Services Organization Inc System and method for providing quality-referenced multimedia
US8989830B2 (en) 2009-02-25 2015-03-24 Valencell, Inc. Wearable light-guiding devices for physiological monitoring
US20150094561A1 (en) * 2012-05-24 2015-04-02 Koninklijke Philips N.V. Reduction of mri interference from the electrocardiogram using lead information
US9044180B2 (en) 2007-10-25 2015-06-02 Valencell, Inc. Noninvasive physiological analysis using excitation-sensor modules and related devices and methods
US9289179B2 (en) 2011-11-23 2016-03-22 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9289175B2 (en) 2009-02-25 2016-03-22 Valencell, Inc. Light-guiding devices and monitoring devices incorporating same
US9320468B2 (en) 2008-01-31 2016-04-26 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US9408566B2 (en) 2006-08-09 2016-08-09 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US9427191B2 (en) 2011-07-25 2016-08-30 Valencell, Inc. Apparatus and methods for estimating time-state physiological parameters
US9439586B2 (en) 2007-10-23 2016-09-13 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US9483608B2 (en) 2007-05-14 2016-11-01 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9541556B2 (en) 2008-05-30 2017-01-10 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US9538921B2 (en) 2014-07-30 2017-01-10 Valencell, Inc. Physiological monitoring devices with adjustable signal analysis and interrogation power and monitoring methods using same
US9558325B2 (en) 2007-05-14 2017-01-31 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US9629578B2 (en) 2006-10-02 2017-04-25 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9730623B2 (en) 2008-03-28 2017-08-15 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9737249B2 (en) 2007-05-14 2017-08-22 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9750462B2 (en) 2009-02-25 2017-09-05 Valencell, Inc. Monitoring apparatus and methods for measuring physiological and/or environmental conditions
US9794653B2 (en) 2014-09-27 2017-10-17 Valencell, Inc. Methods and apparatus for improving signal quality in wearable biometric monitoring devices
US9795326B2 (en) 2009-07-23 2017-10-24 Abbott Diabetes Care Inc. Continuous analyte measurement systems and systems and methods for implanting them
US9795331B2 (en) 2005-12-28 2017-10-24 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US9797880B2 (en) 2007-05-14 2017-10-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9801552B2 (en) 2011-08-02 2017-10-31 Valencell, Inc. Systems and methods for variable filter adjustment by heart rate metric feedback
US9804148B2 (en) 2007-10-23 2017-10-31 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US9804150B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9801571B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9814416B2 (en) 2009-08-31 2017-11-14 Abbott Diabetes Care Inc. Displays for a medical device
US9913600B2 (en) 2007-06-29 2018-03-13 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US9931075B2 (en) 2008-05-30 2018-04-03 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US10009244B2 (en) 2009-04-15 2018-06-26 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US10015582B2 (en) 2014-08-06 2018-07-03 Valencell, Inc. Earbud monitoring devices
US10031002B2 (en) 2007-05-14 2018-07-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10045739B2 (en) 2008-09-30 2018-08-14 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US10076253B2 (en) 2013-01-28 2018-09-18 Valencell, Inc. Physiological monitoring devices having sensing elements decoupled from body motion
US10082493B2 (en) 2011-11-25 2018-09-25 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US10117614B2 (en) 2006-02-28 2018-11-06 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10349874B2 (en) 2009-09-29 2019-07-16 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US10349877B2 (en) 2007-04-14 2019-07-16 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US10413197B2 (en) 2006-12-19 2019-09-17 Valencell, Inc. Apparatus, systems and methods for obtaining cleaner physiological information signals
US10463310B2 (en) 2007-05-14 2019-11-05 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10610158B2 (en) 2015-10-23 2020-04-07 Valencell, Inc. Physiological monitoring devices and methods that identify subject activity type
JP2020153816A (en) * 2019-03-20 2020-09-24 株式会社リコー Magnetic field measuring device and magnetic field measuring method
US10827979B2 (en) 2011-01-27 2020-11-10 Valencell, Inc. Wearable monitoring device
US10945618B2 (en) 2015-10-23 2021-03-16 Valencell, Inc. Physiological monitoring devices and methods for noise reduction in physiological signals based on subject activity type
US10966662B2 (en) 2016-07-08 2021-04-06 Valencell, Inc. Motion-dependent averaging for physiological metric estimating systems and methods
US11298058B2 (en) 2005-12-28 2022-04-12 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US11553883B2 (en) 2015-07-10 2023-01-17 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
US11896371B2 (en) 2012-09-26 2024-02-13 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7286871B2 (en) * 2000-08-15 2007-10-23 The Regents Of The University Of California Method and apparatus for reducing contamination of an electrical signal
US7291123B2 (en) * 2003-06-04 2007-11-06 Gambro Lundia Joint for fluid transport lines for medical use
US7684856B2 (en) * 2005-12-12 2010-03-23 General Electric Company Detection of artifacts in bioelectric signals
US20070135727A1 (en) * 2005-12-12 2007-06-14 Juha Virtanen Detection of artifacts in bioelectric signals

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243045A (en) * 1978-02-10 1981-01-06 Siemens Aktiengesellschaft Method and apparatus for the suppression of interference signals in a useful signal
US4483346A (en) * 1983-08-25 1984-11-20 Intech Systems Corp. Electrocardiograph with digitally-printing waveform display
US4991580A (en) * 1989-03-30 1991-02-12 Invivo Research, Inc. Method of improving the quality of an electrocardiogram obtained from a patient undergoing magnetic resonance imaging
US5038785A (en) * 1985-08-09 1991-08-13 Picker International, Inc. Cardiac and respiratory monitor with magnetic gradient noise elimination
US5269302A (en) * 1991-05-10 1993-12-14 Somatics, Inc. Electroconvulsive therapy apparatus and method for monitoring patient seizures
US5341811A (en) * 1991-03-26 1994-08-30 Allegheny-Singer Research Institute Method and apparatus for observation of ventricular late potentials
US5365428A (en) * 1992-01-21 1994-11-15 Quinton Instrument Company Device and method for reducing number of data sample points sent to a video display system
US5921939A (en) * 1996-04-12 1999-07-13 Siemens Elema Ab Device for monitoring measurement electrodes to detect the presence of faults in electrode, leads and in the connection of the electrodes to a patient
US5924980A (en) * 1998-03-11 1999-07-20 Siemens Corporate Research, Inc. Method and apparatus for adaptively reducing the level of noise in an acquired signal
US6041250A (en) * 1997-05-21 2000-03-21 Quinton Instruments Company Adaptive line noise canceler and detector for ECG signals

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042271A1 (en) * 1990-08-06 1992-02-07 Kevin Scott Kreger Bio-potential signal processor for magnetic resonance imaging
US5368041A (en) * 1992-10-15 1994-11-29 Aspect Medical Systems, Inc. Monitor and method for acquiring and processing electrical signals relating to bodily functions
US7286871B2 (en) * 2000-08-15 2007-10-23 The Regents Of The University Of California Method and apparatus for reducing contamination of an electrical signal

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243045A (en) * 1978-02-10 1981-01-06 Siemens Aktiengesellschaft Method and apparatus for the suppression of interference signals in a useful signal
US4483346A (en) * 1983-08-25 1984-11-20 Intech Systems Corp. Electrocardiograph with digitally-printing waveform display
US5038785A (en) * 1985-08-09 1991-08-13 Picker International, Inc. Cardiac and respiratory monitor with magnetic gradient noise elimination
US4991580A (en) * 1989-03-30 1991-02-12 Invivo Research, Inc. Method of improving the quality of an electrocardiogram obtained from a patient undergoing magnetic resonance imaging
US5341811A (en) * 1991-03-26 1994-08-30 Allegheny-Singer Research Institute Method and apparatus for observation of ventricular late potentials
US5269302A (en) * 1991-05-10 1993-12-14 Somatics, Inc. Electroconvulsive therapy apparatus and method for monitoring patient seizures
US5365428A (en) * 1992-01-21 1994-11-15 Quinton Instrument Company Device and method for reducing number of data sample points sent to a video display system
US5921939A (en) * 1996-04-12 1999-07-13 Siemens Elema Ab Device for monitoring measurement electrodes to detect the presence of faults in electrode, leads and in the connection of the electrodes to a patient
US6041250A (en) * 1997-05-21 2000-03-21 Quinton Instruments Company Adaptive line noise canceler and detector for ECG signals
US5924980A (en) * 1998-03-11 1999-07-20 Siemens Corporate Research, Inc. Method and apparatus for adaptively reducing the level of noise in an acquired signal

Cited By (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025382A1 (en) * 2005-09-01 2007-03-08 Les Systèmes Nuax Computer mouse pressure acquisition module
US10307091B2 (en) 2005-12-28 2019-06-04 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US11298058B2 (en) 2005-12-28 2022-04-12 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US9795331B2 (en) 2005-12-28 2017-10-24 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US11872039B2 (en) 2006-02-28 2024-01-16 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US10117614B2 (en) 2006-02-28 2018-11-06 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US20080004537A1 (en) * 2006-06-30 2008-01-03 Kimmo Uutela Method and system for multi-channel biosignal processing
US11864894B2 (en) 2006-08-09 2024-01-09 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US10278630B2 (en) 2006-08-09 2019-05-07 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US9408566B2 (en) 2006-08-09 2016-08-09 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US9833181B2 (en) 2006-08-09 2017-12-05 Abbot Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US9839383B2 (en) 2006-10-02 2017-12-12 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US10342469B2 (en) 2006-10-02 2019-07-09 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9629578B2 (en) 2006-10-02 2017-04-25 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US11272848B2 (en) 2006-12-19 2022-03-15 Valencell, Inc. Wearable apparatus for multiple types of physiological and/or environmental monitoring
US10987005B2 (en) 2006-12-19 2021-04-27 Valencell, Inc. Systems and methods for presenting personal health information
US11399724B2 (en) 2006-12-19 2022-08-02 Valencell, Inc. Earpiece monitor
US11395595B2 (en) 2006-12-19 2022-07-26 Valencell, Inc. Apparatus, systems and methods for monitoring and evaluating cardiopulmonary functioning
US11350831B2 (en) 2006-12-19 2022-06-07 Valencell, Inc. Physiological monitoring apparatus
US11324407B2 (en) 2006-12-19 2022-05-10 Valencell, Inc. Methods and apparatus for physiological and environmental monitoring with optical and footstep sensors
US8702607B2 (en) 2006-12-19 2014-04-22 Valencell, Inc. Targeted advertising systems and methods
US11295856B2 (en) 2006-12-19 2022-04-05 Valencell, Inc. Apparatus, systems, and methods for measuring environmental exposure and physiological response thereto
US8157730B2 (en) * 2006-12-19 2012-04-17 Valencell, Inc. Physiological and environmental monitoring systems and methods
US11272849B2 (en) 2006-12-19 2022-03-15 Valencell, Inc. Wearable apparatus
US20080146892A1 (en) * 2006-12-19 2008-06-19 Valencell, Inc. Physiological and environmental monitoring systems and methods
US10258243B2 (en) 2006-12-19 2019-04-16 Valencell, Inc. Apparatus, systems, and methods for measuring environmental exposure and physiological response thereto
US11109767B2 (en) 2006-12-19 2021-09-07 Valencell, Inc. Apparatus, systems and methods for obtaining cleaner physiological information signals
US11083378B2 (en) 2006-12-19 2021-08-10 Valencell, Inc. Wearable apparatus having integrated physiological and/or environmental sensors
US11000190B2 (en) 2006-12-19 2021-05-11 Valencell, Inc. Apparatus, systems and methods for obtaining cleaner physiological information signals
US11412938B2 (en) 2006-12-19 2022-08-16 Valencell, Inc. Physiological monitoring apparatus and networks
US10716481B2 (en) 2006-12-19 2020-07-21 Valencell, Inc. Apparatus, systems and methods for monitoring and evaluating cardiopulmonary functioning
US10595730B2 (en) 2006-12-19 2020-03-24 Valencell, Inc. Physiological monitoring methods
US10413197B2 (en) 2006-12-19 2019-09-17 Valencell, Inc. Apparatus, systems and methods for obtaining cleaner physiological information signals
US20110098112A1 (en) * 2006-12-19 2011-04-28 Leboeuf Steven Francis Physiological and Environmental Monitoring Systems and Methods
US20110084714A1 (en) * 2007-02-28 2011-04-14 Cardiac Pacemakers, Inc. Induced Current Measurement Systems And Methods
US7873412B2 (en) 2007-02-28 2011-01-18 Cardiac Pacemakers, Inc. Induced current measurement systems and methods
US8014856B2 (en) 2007-02-28 2011-09-06 Cardiac Pacemakers, Inc. Induced current measurement systems and methods
US20080208276A1 (en) * 2007-02-28 2008-08-28 Cardiac Pacemakers, Inc. Induced Current Measurement Systems And Methods
US10155117B2 (en) 2007-03-09 2018-12-18 Cardiac Pacemakers, Inc. MRI compatible implantable medical devices and methods
US9849292B2 (en) 2007-03-09 2017-12-26 Cardiac Pacemakers, Inc. MRI compatible implantable medical devices and methods
US20080221638A1 (en) * 2007-03-09 2008-09-11 Cardiac Pacemakers, Inc. MRI Compatible Implantable Medical Devices and Methods
US9345888B2 (en) 2007-03-09 2016-05-24 Cardiac Pacemakers, Inc. MRI compatible implantable medical devices and methods
US7853318B2 (en) * 2007-03-14 2010-12-14 Cardiac Pacemakers, Inc. Cardiac sensing by implantable medical devices during magnetic resonance imaging
US20080228092A1 (en) * 2007-03-14 2008-09-18 Wedan Steven R Cardiac Sensing by Implantable Medical Devices During Magnetic Resonance Imaging
US10349877B2 (en) 2007-04-14 2019-07-16 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9797880B2 (en) 2007-05-14 2017-10-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10031002B2 (en) 2007-05-14 2018-07-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10261069B2 (en) 2007-05-14 2019-04-16 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9804150B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9801571B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9737249B2 (en) 2007-05-14 2017-08-22 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10991456B2 (en) 2007-05-14 2021-04-27 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US9483608B2 (en) 2007-05-14 2016-11-01 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11076785B2 (en) 2007-05-14 2021-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10976304B2 (en) 2007-05-14 2021-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10143409B2 (en) 2007-05-14 2018-12-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9558325B2 (en) 2007-05-14 2017-01-31 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US11119090B2 (en) 2007-05-14 2021-09-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11125592B2 (en) 2007-05-14 2021-09-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10820841B2 (en) 2007-05-14 2020-11-03 Abbot Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10119956B2 (en) 2007-05-14 2018-11-06 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10463310B2 (en) 2007-05-14 2019-11-05 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10045720B2 (en) 2007-05-14 2018-08-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10653344B2 (en) 2007-05-14 2020-05-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11828748B2 (en) 2007-05-14 2023-11-28 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10634662B2 (en) 2007-05-14 2020-04-28 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11300561B2 (en) 2007-05-14 2022-04-12 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US11678821B2 (en) 2007-06-29 2023-06-20 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US9913600B2 (en) 2007-06-29 2018-03-13 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US10856785B2 (en) 2007-06-29 2020-12-08 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US9743865B2 (en) 2007-10-23 2017-08-29 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US9439586B2 (en) 2007-10-23 2016-09-13 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US9804148B2 (en) 2007-10-23 2017-10-31 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US9044180B2 (en) 2007-10-25 2015-06-02 Valencell, Inc. Noninvasive physiological analysis using excitation-sensor modules and related devices and methods
US9808204B2 (en) 2007-10-25 2017-11-07 Valencell, Inc. Noninvasive physiological analysis using excitation-sensor modules and related devices and methods
US9320468B2 (en) 2008-01-31 2016-04-26 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US9770211B2 (en) 2008-01-31 2017-09-26 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US9730623B2 (en) 2008-03-28 2017-08-15 Abbott Diabetes Care Inc. Analyte sensor calibration management
US10463288B2 (en) 2008-03-28 2019-11-05 Abbott Diabetes Care Inc. Analyte sensor calibration management
US11779248B2 (en) 2008-03-28 2023-10-10 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9795328B2 (en) 2008-05-30 2017-10-24 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US10327682B2 (en) 2008-05-30 2019-06-25 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US9931075B2 (en) 2008-05-30 2018-04-03 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US9541556B2 (en) 2008-05-30 2017-01-10 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US11735295B2 (en) 2008-05-30 2023-08-22 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US10045739B2 (en) 2008-09-30 2018-08-14 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US20100161779A1 (en) * 2008-12-24 2010-06-24 Verizon Services Organization Inc System and method for providing quality-referenced multimedia
US10842389B2 (en) 2009-02-25 2020-11-24 Valencell, Inc. Wearable audio devices
US10448840B2 (en) 2009-02-25 2019-10-22 Valencell, Inc. Apparatus for generating data output containing physiological and motion-related information
US10973415B2 (en) 2009-02-25 2021-04-13 Valencell, Inc. Form-fitted monitoring apparatus for health and environmental monitoring
US9750462B2 (en) 2009-02-25 2017-09-05 Valencell, Inc. Monitoring apparatus and methods for measuring physiological and/or environmental conditions
US9131312B2 (en) 2009-02-25 2015-09-08 Valencell, Inc. Physiological monitoring methods
US9289135B2 (en) 2009-02-25 2016-03-22 Valencell, Inc. Physiological monitoring methods and apparatus
US10092245B2 (en) 2009-02-25 2018-10-09 Valencell, Inc. Methods and apparatus for detecting motion noise and for removing motion noise from physiological signals
US10542893B2 (en) 2009-02-25 2020-01-28 Valencell, Inc. Form-fitted monitoring apparatus for health and environmental monitoring
US9289175B2 (en) 2009-02-25 2016-03-22 Valencell, Inc. Light-guiding devices and monitoring devices incorporating same
US9301696B2 (en) 2009-02-25 2016-04-05 Valencell, Inc. Earbud covers
US9314167B2 (en) 2009-02-25 2016-04-19 Valencell, Inc. Methods for generating data output containing physiological and motion-related information
US11026588B2 (en) 2009-02-25 2021-06-08 Valencell, Inc. Methods and apparatus for detecting motion noise and for removing motion noise from physiological signals
US10076282B2 (en) 2009-02-25 2018-09-18 Valencell, Inc. Wearable monitoring devices having sensors and light guides
US11589812B2 (en) 2009-02-25 2023-02-28 Valencell, Inc. Wearable devices for physiological monitoring
US11471103B2 (en) 2009-02-25 2022-10-18 Valencell, Inc. Ear-worn devices for physiological monitoring
US10716480B2 (en) 2009-02-25 2020-07-21 Valencell, Inc. Hearing aid earpiece covers
US10750954B2 (en) 2009-02-25 2020-08-25 Valencell, Inc. Wearable devices with flexible optical emitters and/or optical detectors
US10898083B2 (en) 2009-02-25 2021-01-26 Valencell, Inc. Wearable monitoring devices with passive and active filtering
US11660006B2 (en) 2009-02-25 2023-05-30 Valencell, Inc. Wearable monitoring devices with passive and active filtering
US10842387B2 (en) 2009-02-25 2020-11-24 Valencell, Inc. Apparatus for assessing physiological conditions
US8989830B2 (en) 2009-02-25 2015-03-24 Valencell, Inc. Wearable light-guiding devices for physiological monitoring
US11160460B2 (en) 2009-02-25 2021-11-02 Valencell, Inc. Physiological monitoring methods
US9955919B2 (en) 2009-02-25 2018-05-01 Valencell, Inc. Light-guiding devices and monitoring devices incorporating same
US10009244B2 (en) 2009-04-15 2018-06-26 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US10827954B2 (en) 2009-07-23 2020-11-10 Abbott Diabetes Care Inc. Continuous analyte measurement systems and systems and methods for implanting them
US9795326B2 (en) 2009-07-23 2017-10-24 Abbott Diabetes Care Inc. Continuous analyte measurement systems and systems and methods for implanting them
US10123752B2 (en) 2009-08-31 2018-11-13 Abbott Diabetes Care Inc. Displays for a medical device
USRE47315E1 (en) 2009-08-31 2019-03-26 Abbott Diabetes Care Inc. Displays for a medical device
US10881355B2 (en) 2009-08-31 2021-01-05 Abbott Diabetes Care Inc. Displays for a medical device
US9814416B2 (en) 2009-08-31 2017-11-14 Abbott Diabetes Care Inc. Displays for a medical device
US10456091B2 (en) 2009-08-31 2019-10-29 Abbott Diabetes Care Inc. Displays for a medical device
US10772572B2 (en) 2009-08-31 2020-09-15 Abbott Diabetes Care Inc. Displays for a medical device
US10918342B1 (en) 2009-08-31 2021-02-16 Abbott Diabetes Care Inc. Displays for a medical device
US11241175B2 (en) 2009-08-31 2022-02-08 Abbott Diabetes Care Inc. Displays for a medical device
US11202586B2 (en) 2009-08-31 2021-12-21 Abbott Diabetes Care Inc. Displays for a medical device
US11730429B2 (en) 2009-08-31 2023-08-22 Abbott Diabetes Care Inc. Displays for a medical device
US10349874B2 (en) 2009-09-29 2019-07-16 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US10827979B2 (en) 2011-01-27 2020-11-10 Valencell, Inc. Wearable monitoring device
US11324445B2 (en) 2011-01-27 2022-05-10 Valencell, Inc. Headsets with angled sensor modules
US9427191B2 (en) 2011-07-25 2016-08-30 Valencell, Inc. Apparatus and methods for estimating time-state physiological parameters
US9521962B2 (en) 2011-07-25 2016-12-20 Valencell, Inc. Apparatus and methods for estimating time-state physiological parameters
US9788785B2 (en) 2011-07-25 2017-10-17 Valencell, Inc. Apparatus and methods for estimating time-state physiological parameters
US11375902B2 (en) 2011-08-02 2022-07-05 Valencell, Inc. Systems and methods for variable filter adjustment by heart rate metric feedback
US10512403B2 (en) 2011-08-02 2019-12-24 Valencell, Inc. Systems and methods for variable filter adjustment by heart rate metric feedback
US9801552B2 (en) 2011-08-02 2017-10-31 Valencell, Inc. Systems and methods for variable filter adjustment by heart rate metric feedback
US9743872B2 (en) 2011-11-23 2017-08-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US10939859B2 (en) 2011-11-23 2021-03-09 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9289179B2 (en) 2011-11-23 2016-03-22 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US10136847B2 (en) 2011-11-23 2018-11-27 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US10082493B2 (en) 2011-11-25 2018-09-25 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US11391723B2 (en) 2011-11-25 2022-07-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US10231671B2 (en) * 2012-05-24 2019-03-19 Koninklijke Philips N.V. Reduction of MRI interference from the electrocardiogram using lead information
US20150094561A1 (en) * 2012-05-24 2015-04-02 Koninklijke Philips N.V. Reduction of mri interference from the electrocardiogram using lead information
US10942164B2 (en) 2012-08-30 2021-03-09 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10345291B2 (en) 2012-08-30 2019-07-09 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10656139B2 (en) 2012-08-30 2020-05-19 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US11896371B2 (en) 2012-09-26 2024-02-13 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US10856749B2 (en) 2013-01-28 2020-12-08 Valencell, Inc. Physiological monitoring devices having sensing elements decoupled from body motion
US11266319B2 (en) 2013-01-28 2022-03-08 Valencell, Inc. Physiological monitoring devices having sensing elements decoupled from body motion
US11684278B2 (en) 2013-01-28 2023-06-27 Yukka Magic Llc Physiological monitoring devices having sensing elements decoupled from body motion
US10076253B2 (en) 2013-01-28 2018-09-18 Valencell, Inc. Physiological monitoring devices having sensing elements decoupled from body motion
US11185290B2 (en) 2014-07-30 2021-11-30 Valencell, Inc. Physiological monitoring devices and methods using optical sensors
US11412988B2 (en) 2014-07-30 2022-08-16 Valencell, Inc. Physiological monitoring devices and methods using optical sensors
US11337655B2 (en) 2014-07-30 2022-05-24 Valencell, Inc. Physiological monitoring devices and methods using optical sensors
US11638561B2 (en) 2014-07-30 2023-05-02 Yukka Magic Llc Physiological monitoring devices with adjustable signal analysis and interrogation power and monitoring methods using same
US9538921B2 (en) 2014-07-30 2017-01-10 Valencell, Inc. Physiological monitoring devices with adjustable signal analysis and interrogation power and monitoring methods using same
US11179108B2 (en) 2014-07-30 2021-11-23 Valencell, Inc. Physiological monitoring devices and methods using optical sensors
US10893835B2 (en) 2014-07-30 2021-01-19 Valencell, Inc. Physiological monitoring devices with adjustable signal analysis and interrogation power and monitoring methods using same
US11638560B2 (en) 2014-07-30 2023-05-02 Yukka Magic Llc Physiological monitoring devices and methods using optical sensors
US10015582B2 (en) 2014-08-06 2018-07-03 Valencell, Inc. Earbud monitoring devices
US10623849B2 (en) 2014-08-06 2020-04-14 Valencell, Inc. Optical monitoring apparatus and methods
US11252498B2 (en) 2014-08-06 2022-02-15 Valencell, Inc. Optical physiological monitoring devices
US10536768B2 (en) 2014-08-06 2020-01-14 Valencell, Inc. Optical physiological sensor modules with reduced signal noise
US11252499B2 (en) 2014-08-06 2022-02-15 Valencell, Inc. Optical physiological monitoring devices
US11330361B2 (en) 2014-08-06 2022-05-10 Valencell, Inc. Hearing aid optical monitoring apparatus
US10779062B2 (en) 2014-09-27 2020-09-15 Valencell, Inc. Wearable biometric monitoring devices and methods for determining if wearable biometric monitoring devices are being worn
US10382839B2 (en) 2014-09-27 2019-08-13 Valencell, Inc. Methods for improving signal quality in wearable biometric monitoring devices
US10506310B2 (en) 2014-09-27 2019-12-10 Valencell, Inc. Wearable biometric monitoring devices and methods for determining signal quality in wearable biometric monitoring devices
US9794653B2 (en) 2014-09-27 2017-10-17 Valencell, Inc. Methods and apparatus for improving signal quality in wearable biometric monitoring devices
US10798471B2 (en) 2014-09-27 2020-10-06 Valencell, Inc. Methods for improving signal quality in wearable biometric monitoring devices
US10834483B2 (en) 2014-09-27 2020-11-10 Valencell, Inc. Wearable biometric monitoring devices and methods for determining if wearable biometric monitoring devices are being worn
US11553883B2 (en) 2015-07-10 2023-01-17 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
US10945618B2 (en) 2015-10-23 2021-03-16 Valencell, Inc. Physiological monitoring devices and methods for noise reduction in physiological signals based on subject activity type
US10610158B2 (en) 2015-10-23 2020-04-07 Valencell, Inc. Physiological monitoring devices and methods that identify subject activity type
US10966662B2 (en) 2016-07-08 2021-04-06 Valencell, Inc. Motion-dependent averaging for physiological metric estimating systems and methods
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
JP7306003B2 (en) 2019-03-20 2023-07-11 株式会社リコー Magnetic field measurement device and magnetic field measurement method
JP2020153816A (en) * 2019-03-20 2020-09-24 株式会社リコー Magnetic field measuring device and magnetic field measuring method

Also Published As

Publication number Publication date
EP1424637A1 (en) 2004-06-02
US7038601B2 (en) 2006-05-02

Similar Documents

Publication Publication Date Title
US7038601B2 (en) Artifact removal from an electric signal
US4991587A (en) Adaptive filtering of physiological signals in physiologically gated magnetic resonance imaging
Allen et al. A method for removing imaging artifact from continuous EEG recorded during functional MRI
EP1363533B1 (en) Determining heart rate
US6070097A (en) Method for generating a gating signal for cardiac MRI
US5584295A (en) System for measuring the period of a quasi-periodic signal
Deckers et al. An adaptive filter for suppression of cardiac and respiratory noise in MRI time series data
US8121382B2 (en) Method for setting at least one control variable of a filter for noise reduction in medical images
EP1435217A2 (en) Pacemaker pulse detection and artifact rejection
JPH0852117A (en) Patient monitor
JPH0751237A (en) Method and device for raising signal/noise ratio of ecg signal
US10231672B2 (en) ECG signal processing apparatus, MRI apparatus, and ECG signal processing method
WO2013052944A1 (en) Periodic artifact reduction from biomedical signals
EP0104781B1 (en) Reception signal processing apparatus in nuclear magnetic resonance diagnostic apparatus
US20110144461A1 (en) Pulse frequency measuring method and apparatus
EP1972273A2 (en) Brain wave measuring method, apparatus and computer readable recording medium implemented with program for executing the method
EP3295204B1 (en) Systems and methods for calibrated multi-spectral magnetic resonance imaging
JPH10262941A (en) Electroencephalogram processor
US6226549B1 (en) Method for classifying a time series, that includes a prescribable plurality of samples, with a computer
JP4717422B2 (en) MR image generation method, MRI apparatus, and program causing computer to execute the method
EP0634137B1 (en) Device for eliminating ringings in filtered ECG-signals
JPH08266502A (en) Mr imaging system
JPH08336502A (en) Method and device for heartbeat interval detection
US6546361B2 (en) Method for recording and removing the bipolar bias from a vibration input signal
KR100827059B1 (en) Mr imaging method and mri apparatus

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSTRUMENTARIUM CORP., FINLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UUTELA, KIMMO HENRIK;RANTALA, TOR BORJE;VIRTANEN, JUHA PETRI;REEL/FRAME:015208/0385;SIGNING DATES FROM 20031124 TO 20031204

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20140502